Prophylaxis of organ rejection in renal transplantation
Administered once daily to a maximum dose of 40mg/day. See professional literature for details.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It binds to the FK Binding Pro-tein-12 [FKBP-12] generating an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin [mTOR] - a key regulatory kinase. It is this inhibition that suppresses cytokine-driven T-cell proliferation resulting in inhibiting G1 to the S phase progression of the cell cycle.
Vaccinations; increased risk to infections; allergy to macrolides; Therapeutic drug monitoring [TMD] is recommended for all patients receiving this drug.
Hypersensitivity; pregnancy; lactation
Increased susceptibility to infection, lymphoma, and malignancy; Excess mortality, graft loss, and hepatic artery thrombosis in liver transplant patients; peripheral edema, hypertriglyceridemia, hypertension, hypercholesterolemia, creatinine increased, constipation, abdominal pain, diarrhea, headache, fever, urinary tract infection, anemia, nausea, arthralgia, pain, and thrombocytopenia.
/// Drug interactions: Live attenuated vaccines, clotrimazole, danazol, dexamethasone, methylprednisolone
///Sirolimus (rapamycin) is produced by Streptomyces hygroscopicus.